Compare · KRMD vs WST
KRMD vs WST
Side-by-side comparison of KORU Medical Systems Inc. (KRMD) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KRMD and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $26.37B, about 183.6x KRMD ($143.6M).
- KRMD has been more active in the news (6 items in the past 4 weeks vs 4 for WST).
- WST has more recent analyst coverage (20 ratings vs 6 for KRMD).
- Company
- KORU Medical Systems Inc.
- West Pharmaceutical Services Inc.
- Price
- -
- -
- Market cap
- $143.6M
- $26.37B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 6
- 4
- Recent ratings
- 6
- 20
KORU Medical Systems Inc.
Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. It also provides education and training materials to clinicians, patients, and patient advocates. The company sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest KRMD
- Director Manko Joseph M. Jr. was granted 5,119 shares (SEC Form 4)
- Director Wholihan Edward was granted 5,119 shares, increasing direct ownership by 10% to 56,431 units (SEC Form 4)
- Director French Donna was granted 5,119 shares, increasing direct ownership by 5% to 103,633 units (SEC Form 4)
- Director Cascella Robert was granted 5,119 shares, increasing direct ownership by 5% to 103,274 units (SEC Form 4)
- Chairman of the Board Fletcher R John was granted 7,679 shares, increasing direct ownership by 3% to 239,836 units (SEC Form 4)
- Director Matin Shahriar was granted 5,119 shares, increasing direct ownership by 5% to 106,263 units (SEC Form 4)
- Chief Commercial Officer Kalbermatten Adam R bought $101,120 worth of shares (32,000 units at $3.16), increasing direct ownership by 9% to 394,017 units (SEC Form 4)
- Chief Commercial Officer Kalbermatten Adam R converted options into 75,000 shares and covered exercise/tax liability with 25,483 shares, increasing direct ownership by 16% to 362,017 units (SEC Form 4) to satisfy withholding obligation
- SEC Form 10-Q filed by KORU Medical Systems Inc.
- KORU Medical Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest WST
- West to Host Third-Quarter 2026 Conference Call
- West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Pharm upgraded by Morgan Stanley with a new price target
- Sr. VP & Chief HR Officer Favorite Annette F exercised 7,524 shares at a strike of $89.64 and sold $2,671,260 worth of shares (7,524 units at $355.03) (SEC Form 4)
- Sr. VP & Chief HR Officer Favorite Annette F exercised 8,135 shares at a strike of $85.37 and sold $2,772,489 worth of shares (8,135 units at $340.81) (SEC Form 4)
- SEC Form 4 filed by President and CEO Lagarde Michel
- New insider Lagarde Michel claimed ownership of 7,850 shares (SEC Form 3)
- UBS resumed coverage on West Pharm with a new price target
- West to Participate in Upcoming Investor Conferences